Dear sugood: The doctor at Dana Farber may be referring to a study that was done in Europe comparing CMF chemotherapy to Lupron and Tamoxifen. In this study, the two regimens were found to have comparable results. The potential flaw in this study is that the standard of care has been that chemotherapy is generally followed by tamoxifen in ER+ women. Would the addition of tamoxifen have made the outcome from the chemo arm of the study better? Also, this study compares CMF chemotherapy. In the U.S., the current standard of care is generally AC (adriamycin and cytoxan) - I think this is what the one oncologist recommended. When compared to CMF, AC is superior in terms of outcome. So, if in the European study, AC were substitued for the CMF, would the outcomes still be equal? In most cases, in the U.S., the recommendation for your wife would be 4 cycles of AC followed by 5 years of tamoxifen (lupron could be given in addition to induce menopause). You could, of course, seek another opinion to get clarification.